[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transgender-individuals\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transgender-individuals":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100575574","swiss-prospective-cohort-of-transgender-and-gender-diverse-individuals---the-spectra-study-100575574",false,"NCT06774053","Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","Swiss Prospective Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","SPECTRA","Inclusion Criteria:\n\n* Age 16 years and above.\n* Established diagnosis of gender incongruence\n* Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Missing commitment or ability to study protocol adherence","ALL","16 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.\n\nThe main question is:\n\nWhat are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?\n\nResearchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.\n\nParticipants will:\n\nComplete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.\n\nProvide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.\n\nUndergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.",[25,26],"Transgender Individuals","Gender Incongruence",[28,29,30],"Gender Affirming Hormone Therapy (GAHT)","Gender Affirming Surgery (GAS)","Transgender and Gender Diverse (TGD)","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2026-04-20",{"date":39,"type":21},"2046-01",{"name":41,"class":42},"University Hospital, Basel, Switzerland","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100634690","transgender-analysis-of-nephrological-studies-focused-on-renal-metrics-100634690","NCT07542964","Transgender Analysis of Nephrological Studies Focused on Renal Metrics","TRANSFORM","Inclusion Criteria:\n\n* Diagnosed with gender dysphoria according to DSM-V\n* Expected to start gender-affirming hormone treatment in the upcoming month\n\nExclusion Criteria:\n\n* Current or prior use of gender-affirming hormone therapy\n* Participation in other studies\n* Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)\n* Known kidney disease (eGFR \\\u003C 60 ml\u002Fmin; UACR \\> 2.5 mg\u002Fmmol)\n* Diabetes mellitus\n* A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease, or a previously undiagnosed arrhythmia)\n* Known iodine-related allergies\n* Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)\n* Pregnancy\n* Claustrophobia","18 Years","40 Years",{"count":53,"type":21},60,"This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.",[56,57,25],"Kidney Disease","Kidney Injury",[59,60,61,62,63],"Transgender individuals","Kidney disease","Kidney injury","Gender affirming hormone treatment","Sex hormones","NOT_YET_RECRUITING","2026-04-17",{"date":67,"type":35},"2026-04-21",{"date":69,"type":21},"2026-09",{"date":71,"type":21},"2028-09",{"name":73,"class":42},"Amsterdam UMC, location VUmc",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":74},"100623266","effects-of-gender-affirming-hormone-therapy-on-cardiovascular-metabolic-and-mental-health-outcomes-in-transgender-adults-100623266","NCT07394400","Effects of Gender-Affirming Hormone Therapy on Cardiovascular, Metabolic, and Mental Health Outcomes in Transgender Adults.","A Comprehensive Assessment of the Impact of Gender-Affirming Hormone Therapy on Cardiovascular Risk, Metabolic Health, and Mood Disorders in Transgender Individuals.","Inclusion Criteria:\n\n* Trans men and trans women over the age of 16\n\nExclusion Criteria:\n\n* systemic inflammatory diseases\n* uncontrolled infections\n* severe autoimmune diseases intersex biological conditions (resistance, severe sexual development or chromosomal abnormalities, congenital adrenal hyperplasia)\n* treatment with metformin, statins or oral contraceptives in the previous 6 months\n* serious life-threatening diseases\n* diseases that compromise follow-up\n* BMI higher than 35",true,{"count":84,"type":21},94,"12 Months","The objective of this observational study is to examine the impact of gender-affirming hormone therapy (GAHT) on mood in transgender individuals and to explore its potential association with early atherosclerotic processes. The main questions it aims to answer are:\n\n* Whether GAHT in transgender individuals has a psychological and functional impact, assessed through mood, stress, and self-esteem. Additionally, the study will analyze whether morphofunctional changes (including body composition, muscle strength, cardiorespiratory fitness, and metabolic flexibility) are related to inflammatory responses and psychological well-being.\n* Whether the administration of GAHT poses a cardiovascular risk by influencing biochemical, inflammatory, and oxidative markers, mitochondrial function, and the activation of the NLRP3 inflammasome in leukocytes.\n\nParticipants will undergo evaluation of early stages of the atherosclerotic process through the analysis of leukocyte-endothelial interactions, adhesion molecule expression, and ankle-brachial index (ABI), as well as periodontal parameters. Overall, this study aims to contribute to improving healthcare delivery and promoting more equitable and gender-affirming medical services tailored to the needs of transgender individuals.",[25],[89,90,91,92,93],"GAHT","inflammation","atherosclerosis","periodontal disease","Transgender","2026-02-03",{"date":96,"type":35},"2026-02-06",{"date":98,"type":21},"2026-02-14",{"date":100,"type":21},"2029-12-31",{"name":102,"class":42},"Milagros Rocha Barajas"]